Novo Nordisk tests own mobile app in phase III trial with insulin hope

An internally-developed mobile app from Novo Nordisk will be part of a phase III trial involving the pharmaceutical company's grand hope insulin icodec. This app will help diabetes patients find their optimal insulin doses based on earlier doses and their blood sugar levels.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk has started testing a hitherto-unknown app for people's phones which will help diabetes patients find their recommended doses based on their blood sugar levels and the insulin doses that they have already ingested, according to a report for the database Clinical Trials, which gathers info on clinical trials.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading